Trial Profile
An Open-Label, Multi-Center, Ascending, Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 31 Mar 2009 New trial record
- 31 Mar 2009 New trial record